|  | Taking the Fight to Rare Cancers Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for Biotech℠ |
Today's Rundown Featured Story | | | Friday, October 4, 2019 Zombie biotech Dynavax will lose its chief scientific officer in December, but after a host of cuts, it won’t be looking for a new one. |
|
|---|
|
Top Stories Friday, October 4, 2019 Arbutus is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis—the disease the drug was supposed to treat. It's designed to attack the protein shell protecting the virus’ genetic material. Friday, October 4, 2019 Arcellx has raised $85 million to advance cell therapies designed to be safer and more effective than conventional CAR-Ts. The series B will equip Arcellx to move an anti-BCMA candidate into the clinic in multiple myeloma. Monday, September 30, 2019 Personalized medicine, greater drug portfolio complexity, and quicker clinical development is raising the stakes. How can digital provide a boost in clinical supply chain performance? Friday, October 4, 2019 Takeda has formed an inflammatory bowel disease (IBD) R&D pact with Prometheus Biosciences. The agreement tasks Prometheus with identifying and validating three IBD drug targets in return for up to $420 million in milestones. Thursday, October 3, 2019 Before Donald Trump became U.S. president, he warned pharma he’d be the one to crack down on the industry. Now, as Democrats advance an impeachment inquiry, he said it wouldn't surprise him if pharma companies were behind the effort. Thursday, October 3, 2019 In this week's EuroBiotech Report, Novartis' asthma drug clears late-phase test, Adaptimmune posts cell therapy data and AstraZeneca inks trial deal. Friday, October 4, 2019 Sanofi slims down in Japan after other cuts in Europe and the U.S. Several CEOs of Big Pharma companies have got themselves Chinese names. Astellas and Seattle Genetics, Merck and Eisai and Chi-Med unveiled positive results at ESMO. And more. Friday, October 4, 2019 Pfizer's Read set to step down at year's end; Hahn rumored as next FDA chief; Biogen R&D head Ehlers out after Alzheimer's flop. |  | Congratulations to the Fierce 15 You have proven that great innovations are created with breakthrough science, insightful leaders and unwavering resolve. Thank you. And we look forward to helping you advance to your next milestone. |
Resources Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Outer Edge Technology Find out how outsourcing your IT requirements enhances the bottom line while creating strategic advantage. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. | 
